Finished product reference
Acetylcholine Chloride
Injection · Ophthalmic · 1 % · 2 mL
- List code
- 15
Indications
INDICATIONS AND USAGE To obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy, and other anterior segment surgery where rapid miosis may be required.
Dosage and administration (summary)
DOSAGE AND ADMINISTRATION Miochol ™ -E (acetylcholine chloride intraocular solution) is instilled into the anterior chamber before or after securing one or more sutures. Instillation should be gentle and parallel to the iris face and tangential to pupil border. If there are no mechanical hindrances, the pupil starts to constrict in seconds and the peripheral iris is drawn away from the angle of the anterior chamber. Any anatomical hindrance to miosis must be released to permit the desired effect of the drug. In most cases, 0.5 to 2 mL produces satisfactory miosis. Note that the syringe filter supplied with Miochol-E has a priming volume of 0.6 mL (approximately).
Contraindications
CONTRAINDICATIONS Miochol-E is contraindicated in persons with a known hypersensitivity to any component of this product.
Warnings and precautions
WARNINGS DO NOT GAS STERILIZE. If blister or peelable backing is damaged or broken, sterility of the enclosed vial and ampule cannot be assured. Open under aseptic conditions only.
Storage and supply
HOW SUPPLIED Miochol ™ -E (acetylcholine chloride intraocular solution)............................NDC 24208-539-20 One blister pack containing the following components: • Vial of 20 mg acetylcholine chloride powder for intraocular solution • Ampule of 2 mL diluent One 0.2 micron sterile filter • Priming volume 0.6 mL (approximately) Storage Store …
Source: Acetylcholine Chloride (Miochol E) — US FDA prescribing information, 2023-03-17, DailyMed. Summarised and shortened; the full label governs. Iranian registration, indications and labelling may differ.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.